AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10921143
Drug: Tong Luo
RxNorm normalized name: CAMPHOR (NATURAL) 5 g / MENTHOL 3.4 g TRANSDERMAL POULTICE [TONG LUO QU TONG GAO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tong Luo Kai Bi Tablets
Trial: 10921143
Drug: Rheumatic Semen
RxNorm normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheumatic Semen Strychni Tablets
Trial: 1665177
Drug: Lisinopril-hydrochlorothiazide 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril-hydrochlorothiazide 20 mg and 12.5 mg (L/HCTZ)
Trial: 1665177
Drug: Lisinopril 40
RxNorm normalized name: lisinopril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 40 mg once daily (L40)
Trial: 26682721
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 8 mg
Trial: 29773484
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 8 mg
Trial: 26682721
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline 0.9%
Trial: 21905001
Drug: Ocrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 200 mg
Trial: 21905001
Drug: Ocrelizumab 500
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 500 mg
Trial: 20390409
Drug: Intramuscular clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular clodronate at a dose of 100 mg weekly for 12 months
Trial: 12418424
Drug: Nitrates administered
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates administered orally and/or transdermally
Trial: 9659191
Drug: alpha tocopherol
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha tocopherol (vitamin E) 50 mg/day
Trial: 9659191
Drug: alpha tocopherol
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha tocopherol (vitamin E) 50 mg/day and beta carotene 20 mg/day
Trial: 9659191
Drug: beta carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta carotene 20 mg/day
Trial: 8618789
Drug: Indomethacin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (3 x 0.2 mg/kg/12 h)
Trial: 8618789
Drug: Aspirin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (4 x 15 mg/kg/6 h)
Trial: 2744182
Drug: Sequential embryo
RxNorm normalized name: human embryo tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential embryo transfer at 44 to 48 and 68 to 72 hours after insemination
Trial: 30242736
Drug: Tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tedizolid phosphate (200 mg once daily for 6 days)
Trial: 23403680
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg every 12 hours for 10 days)
Trial: 20131551
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem hydrochloride ointment (2%)
Trial: 20131551
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate ointment (0.2%)
Trial: 15651756
Drug: Twice-daily indinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily indinavir/ritonavir (800/100 mg) regimen
Trial: 15651756
Drug: Three-times-daily indinavir
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times-daily indinavir regimen
Trial: 10808389
Drug: Atenolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25 mg)
Trial: 8582096
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (SV) 400 mg
Trial: 3029790
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (SV) 800 mg
Trial: 12665
Drug: High-dose lorazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lorazepam
Trial: 12665
Drug: Low-dose lorazepam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lorazepam
Trial: 30785704
Drug: Buccal graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal graft
Trial: 18767579
Drug: Cranial needling
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial needling plus medication
Trial: 10233187
Drug: Tinidazole 500
RxNorm normalized name: tinidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 500 mg (OCT)
Trial: 10233187
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg (OCM)
Trial: 7759660
Drug: Metyrapone and
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metyrapone and hydrocortisone (30 mg daily hydrocortisone)
Trial: 25683704
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (4 g)
Trial: 21748500
Drug: Prophylactic hypervolemic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic hypervolemic therapy
Trial: 21748500
Drug: Hyperdynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperdynamic therapy
Trial: 19522983
Drug: High-dose squalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose squalene (27 g/day)
Trial: 19522983
Drug: Low-dose squalene
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose squalene (13.5 g/day)
Trial: 19522983
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of squalene
Trial: 11710709
Drug: Ginger extract
RxNorm normalized name: ginger extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract (EV.EXT 77), administered twice daily for 6 weeks
Trial: 10150223
Drug: Pre-hospital beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital beta-blocker treatment (intravenous injection of atenolol)
Trial: 10150223
Drug: Pre-hospital placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital placebo treatment
Trial: 12791627
Drug: 240 mL
RxNorm normalized name: Iron 5 MG/240 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mL orange juice fortified with 1000 IU vitamin D(3) daily for 12 weeks
Trial: 10815856
Drug: Flashlamp‐pumped pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas
Trial: 10815856
Drug: Flashlamp‐pumped pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for mixed hemangiomas
Trial: 10815856
Drug: Flashlamp‐pumped pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas in involution phase
Trial: 8970899
Drug: 1.2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/day of oral calcium as carbonate
Trial: 26780938
Drug: Immediate discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate discontinuation group (IDG)
Trial: 24650219
Drug: Daily 20
RxNorm normalized name: Culturelle Probiotics Digestive Daily 200mg-10 Billion CFU Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 20 g lipid-based multi-micronutrient (MMN) supplement; additional 300 kcal/d for women with BMI <20 or low gestational weight gain
Trial: 22436129
Drug: Allopurinol 200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 200/300 mg
Trial: 17495810
Drug: Calcium hydroxyapatite
RxNorm normalized name: Calcium hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxyapatite preparations
Trial: 14962813
Drug: raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raloxifene (60 or 120 mg/day)
Trial: 11591882
Drug: Glycerol ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol ingestion (1 g glycerol in 20 ml H2O x kg(‐1) body weight)
Trial: 11591882
Drug: Control (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (20 ml H2O x kg(‐1) body weight)
Trial: 2928998
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol (400, 600, and 800 micrograms)
Trial: 2928998
Drug: Inhaled isoprenaline
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled isoprenaline (400, 600, and 800 micrograms)
Trial: 2928998
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (400, 600, and 800 micrograms)
Trial: 26316325
Drug: Epratuzumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab (1,200 mg infusions at weeks 0 and 2 of repeating 12-week cycles) plus standard of care
Trial: 17373638
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg qd
Trial: 25867771
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin qd
Trial: 23673304
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (COMBO)
Trial: 20608826
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of depression in patients with heart disease; specific intervention details not available.
Trial: 20608826
Drug: Recognition and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recognition and treatment of depression; specific intervention details not available.
Trial: 10521635
Drug: Lateral glide
RxNorm normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lateral glide treatment technique
Trial: 1679870
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin and aerosol inhalations of colistin twice daily for 3 weeks
Trial: 1679870
Drug: No anti-pseudomonas
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-pseudomonas chemotherapy
Trial: 22559269
Drug: Prophylactic intra-graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intra-graft administration of abciximab and verapamil followed by direct stenting (n=91)
Trial: 19280232
Drug: Bone substitutes
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone substitutes (allografts, ceramics, demineralized bone matrix, osteoinductive factors, autogenous platelet concentrate, mesenchymal stem cells, gene therapy)
Trial: 12556375
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg ciprofloxacin (one dose)
Trial: 12556375
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg ciprofloxacin (two doses every 12 hours)
Trial: 10997367
Drug: Thickened formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thickened formula (0.4 g galactomannan per 100 ml diluted milk)
Trial: 1950094
Drug: Trivalent split
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent split influenza vaccine
Trial: 1950094
Drug: Trivalent subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent subunit influenza vaccine
Trial: 15280979
Drug: Intravenous hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hyoscine
Trial: 28092404
Drug: Myoinositol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myoinositol (1000 mg twice a day)
Trial: 25638326
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (15 mg/kg intravenously on day 1 or 2)
Trial: 17306016
Drug: Bolus hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bolus hydrocortisone (200 mg/day)
Trial: 17306016
Drug: Continuous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous hydrocortisone infusion (200 mg/day)
Trial: 10381298
Drug: Fluvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin treatment for 52 weeks
Trial: 8730228
Drug: Diazepam (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (four logarithmically increasing doses)
Trial: 8730228
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four logarithmically increasing doses)
Trial: 1888825
Drug: ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (300 mg nocte)
Trial: 1888825
Drug: cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine (800 mg nocte)
Trial: 1888825
Drug: famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine (40 mg nocte)
Trial: 6337578
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride with behavior therapy (BT)
Trial: 6337578
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with behavior therapy (BT)
Trial: 30591285
Drug: Immunosuppressants
RxNorm normalized name: IMMUNOSUPPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressants
Trial: 30247524
Drug: Bevacizumab (B)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (B) added to chemotherapy (capecitabine (C)±mitomycin (M))
Trial: 30247524
Drug: Bevacizumab (B)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (B) added to first-line capecitabine-based chemotherapy
Trial: 17915999
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus 3 days of AZM, 500 mg
Trial: 12114037
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta‐carotene daily)
Trial: 9579771
Drug: Irbesartan 75
RxNorm normalized name: irbesartan 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 75 mg
Trial: 10193713
Drug: Irbesartan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (all doses)
Trial: 10193713
Drug: Irbesartan (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (75 mg and 150 mg)
Trial: 7474602
Drug: Bilateral orchiectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral orchiectomy and 25 mg/day of etoposide every 2 weeks for 6 months
Trial: 7474602
Drug: Bilateral orchiectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral orchiectomy and 560 mg/day of estramustine phosphate for 6 months
Trial: 7860471
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg once daily
Trial: 108152
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllocontin tablets (12.5 mg/kg)
Trial: 108152
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllocontin tablets (12.5 mg/kg twice daily)
Trial: 17853036
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg intravenously 60 min before the procedure
Trial: 17853036
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg intravenously 60 min before the procedure
Trial: 16027246
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (DC) 100 g per day (containing 88 mg flavanols)
Trial: 16027246
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (DC) 100 g per day
Trial: 16027246
Drug: Flavanol-free white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-free white chocolate (WC) 90 g per day
Trial: 10643800
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg) and placebo beverage
Trial: 10643800
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill and alcohol (0.55 g/kg in 10% (v/v) solution)
Trial: 10643800
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill and placebo beverage
Trial: 8865536
Drug: Protein C,
RxNorm normalized name: protein C, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein C, Antithrombin III, Heparin-Cofactor II, and plasminogen levels
Trial: 8865536
Drug: Pill use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill use
Trial: 6528679
Drug: Citrate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate infusion
Trial: 29652271
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 μg/kg/min) administered preoperatively for 24 hours including intraoperative period
Trial: 24894735
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (3 × 1 h weekly sessions)
Trial: 24894735
Drug: Dissonance-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissonance-based intervention (3 × 1 h weekly sessions)
Trial: 22728005
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention with optimal medical therapy
Trial: 16009170
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate instillation (300 mL)
Trial: 12406833
Drug: Mepolizumab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (750 mg, three intravenous doses over 20 weeks)
Trial: 11762559
Drug: Intravenous itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous itraconazole 200 mg twice daily for 2 days, then once daily for 5 days
Trial: 11762559
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole solution 200 mg twice daily
Trial: 11762559
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole solution 200 mg once daily
Trial: 11762559
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with itraconazole
Trial: 17017665
Drug: Intravenous itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous itraconazole
Trial: 9205678
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral prednisolone and cyclophosphamide followed by azathioprine (CCAZP)
Trial: 7679560
Drug: Morphine (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.16 mg.kg‐1)
Trial: 7679560
Drug: Diamorphine (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine (0.08 mg.kg‐1)
Trial: 2887152
Drug: Vigabatrin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (2 to 3 g/d, stratified according to weight)
Trial: 31434737
Drug: DNA/rAd5 HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA/rAd5 HIV vaccine regimen
Trial: 31434737
Drug: Anti-gp140 antibody-dependent
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-gp140 antibody-dependent cellular phagocytosis
Trial: 27132450
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia with 0.05 mg/kg intravenous bolus, then continuous infusion of 0.02‐0.10 mg x kg(‐1) x h(‐1)